Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies

Next Previous
Trial Profile

CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 13 Dec 2022 Results assessing benefits of a second Allo-HSCT after CAR-T Cell therapy presented at the 64th American Society of Hematology Annual Meeting and Exposition
  • 01 Mar 2022 Results from rom 5 clinical trials (NCT03173417, NCT02546739, NCT03671460, ChiCTR-ONC-17012829, and ChiCTR1800016541) assessing Factors associated with treatment response to CD19 CAR-T therapy among a large cohort of B cell acute lymphoblastic leukemia published in the Cancer Immunology Immunotherapy
  • 08 Dec 2020 Results of pooled analysis of a data pooled from NCT03173417; NCT02546739; and ChiCTR-ONC-17012829 studies assessing the feasibility and efficacy in 37 patients with refractory/relapsed (R/R) B-ALL who received CAR T-cells derived from related donors, presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top